WA
CRSP icon

Whipplewood Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Whipplewood Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,392
Closed -$161K – 734
2026
Q1 		$161K Hold
3,392
– – 0.08% 149
2025
Q4 		$178K Hold
3,392
– – 0.11% 130
2025
Q3 		$220K Sell
3,392
-745
-18% -$42.8K 0.14% 116
2025
Q2 		$201K Buy
4,137
+4,132
+82,640% +$160K 0.11% 166
2025
Q1 		$137K Sell
5
-4,032
-100% -$171K 0.08% 190
2024
Q4 		$159K Buy
+4,037
New +$191K 0.09% 185

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Whipplewood Advisors's CRSP Position: Q2 2026 in Review

Whipplewood Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 3,392 shares — an estimated $161K sold.

Whipplewood Advisors first reported a position in CRSP in Q4 2024 and held it in 6 quarters. The position peaked at $220K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Whipplewood Advisors reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Whipplewood Advisors sold 3,392 CRISPR Therapeutics shares in Q2 2026, an estimated $161K.
  • Whipplewood Advisors first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 6 quarters.
  • Whipplewood Advisors's CRISPR Therapeutics position peaked at $220K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.